 |
|
|
| |
Evaluation of Tenofovir Alafenamide Pharmacokinetics:
No Influence of Demographic or HIV Disease Factors
|
| |
| |
......No Relationship Between TAF and TFV PK and Gender, Race, Age .....PK Comparable in Treatment Naïve vs Virologically Suppressed Patients....Across HIV Disease Factors - baseline CD4 & viral load.....TAF and TFV PK vs HIV RNA (copies/mL).....TAF PK Comparable Across Renal Function (eGFR [mL/min])* ......
Reported by Jules Levin
EACS 2015 Oct 21-24 Barcelona, Spain
Joseph M. Custodio,1 Feng Jin,1 Leonid Gibiansky,2 William Garner,1 Lijie Zhong,1 Andrew Plummer,1 Marshall Fordyce,1 Scott McCallister,1 Julia Z. Zack1
1Gilead Sciences, Inc., Foster City, California, USA; 2QuantPharm LLC, North Potomac, Maryland, USA
CROI: Safety of Tenofovir Alafenamide in Renal Impairment - (02/27/15)
References
1. Babusis D, et al. Mol Pharm 2013;10:459-66; 2. Birkus G, et al. Antimicrob Agents Chemother 2007;51:543-50; 3. Lee W, et al. Antimicrob Agents Chemother 2005;49:1898-906; 4. Ruane P, et al. J Acquir Immune Defic Syndr 2013;63:449-5; 5. Sax P, et al. J Acquir Immune Defic Syndr 2014;67:52-8;
6. Sax PE, et al. Lancet 2015;385:2606-15; 7. Van Rompay KK, et al. Antimicrob Agents Chemother 2008;52:3144-60; 8. Lee WA, et al. Antimicrob Agents Chemother 2005;49:1898-906; 9. Lindbom L. Comput Methods Programs Biomed 2005;79:241-57; 10. Jin F, et al. 16th International Workshop on
Clinical Pharmacology of HIV & Hepatitis Therapy 2015, poster 40; 11. Zhu L, et al. 9th International Workshop on Pharmacology of HIV Therapy, 2008; 12. Hoetelmans RM, et al. Br J Clin Pharmacol 2007;64:655-61; 13. Kearney BP, et al. J Acquir Immune Defic Syndr 2006;43:278-83; 14. Chittick GE,
et al. Antimicrob Agents Chemother 2006;50:1304-10; 15. Hoetelmans R, et al. 6th International Workshop on Clinical Pharmacology of HIV Therapy, 2005; 16. Atripla [package insert]. Bristol-Myers Squibb, Gilead; 2015; 17. Stribild [package insert]. Foster City, CA: Gilead Sciences, Inc; 2015.
|
| |
|
|
|
|
|
